Alvotech, Kashiv, and Advanz announce successful efficacy study results for AVT23, a proposed biosimilar to Xolair® for CSU treatment.

Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants Elgan Pharma and Chiesi Group ...

Using AI to Predict Launch Success A feature published by Pharmaceutical Executive authored by Anirudh Singh Rathore, Senior Principal of Commercial Solutions, IQVIA and Anirudh Singh Rathore, ...

Objectives To assess the upstream pharmaceutical supply chains of 10 high-use pharmaceuticals to detect vulnerabilities that may increase the risk of medicine shortages. Design Cohort study. Setting ...

BOSTON-- (BUSINESS WIRE)--Cycle Pharmaceuticals Limited (Cycle) announced today the launch of VENXXIVA (tiopronin) Delayed-Release Tablets, for the treatment of cystinuria, approved by the US Food and ...

In a case study of its so-called “drug of the year,” Trinity noted that argenx was able to successfully secure market-leader status for Vyvgart soon after its launch thanks to its “safer ...

With numerous companies investing in novel primary immune deficiency therapies, the pharmaceutical product launch of emerging treatments is expected to reshape the competitive landscape significantly.

Verona Pharma reports $36.6 million in Ohtuvayre sales for Q4 2024, with ongoing Phase 2 trials advancing.

In the dynamic pharmaceutical industry, successful product launches are critical to business success. For small and midsized biotech firms, where the reliance on a few key assets is high, the stakes ...

Traws Pharma (TRAW) announced completion of Phase I clinical studies of its investigational one-dose influenza therapy, tivoxavir marboxil, for the treatment or prevention of H5N1 bird flu.